May. 31 at 5:36 PM
$STIM Neuronetics Inc (Greenbrook) is the single largest branded clinic network supporting Spravato in the country. Greenbrook operates a network of 95+ treatment clinics across the United States
The rapid growth of the SPRAVATO® market acts as a massive financial tailwind and operational catalyst for Greenbrook TMS treatment centers.
The Total Addressable Market (TAM) for SPRAVATO® nasal spray is defined by the global population suffering from Treatment-Resistant Depression (TRD) and major depressive disorder (MDD) with acute suicidal ideation.
The global TRD treatment market—the direct TAM for this drug—is valued at approximately
$2.4 billion to
$2.67 billion, while the specific addressable market for esketamine therapies has grown into a
$1.67 billion segment.
